CCL25 and COVID-19: A recent observational study showed that patients with COVID-19 had elevated plasma levels of LBP and CCL-25, but not of I-FABP and, among them, subjects with cardiac involvement exhibited the highest levels of these biomarkers, suggesting a potential gut-heart axis in COVID-19 (24).